These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 22710649

  • 1. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.
    Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, Lloyd E, Kupfer S.
    Hypertension; 2012 Aug; 60(2):310-8. PubMed ID: 22710649
    [Abstract] [Full Text] [Related]

  • 2. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.
    Bakris GL, Sica D, White WB, Cushman WC, Weber MA, Handley A, Song E, Kupfer S.
    Am J Med; 2012 Dec; 125(12):1229.e1-1229.e10. PubMed ID: 22939358
    [Abstract] [Full Text] [Related]

  • 3. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study.
    Sica D, Bakris GL, White WB, Weber MA, Cushman WC, Huang P, Roberts A, Kupfer S.
    J Clin Hypertens (Greenwich); 2012 May; 14(5):284-92. PubMed ID: 22533654
    [Abstract] [Full Text] [Related]

  • 4. Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide.
    Neutel JM, Cushman WC, Lloyd E, Barger B, Handley A.
    J Clin Hypertens (Greenwich); 2017 Sep; 19(9):874-883. PubMed ID: 28681550
    [Abstract] [Full Text] [Related]

  • 5. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
    White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S.
    Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
    [Abstract] [Full Text] [Related]

  • 6. A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension.
    Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, Lloyd E, Kupfer S.
    J Hypertens; 2018 Apr; 36(4):947-956. PubMed ID: 29334491
    [Abstract] [Full Text] [Related]

  • 7. Azilsartan medoxomil/chlorthalidone: a new fixed-dose combination antihypertensive.
    Pierini D, Anderson KV.
    Ann Pharmacother; 2013 May; 47(5):694-703. PubMed ID: 23585646
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of azilsartan medoxomil with chlorthalidone in hypertension.
    Baker WL, Nigro SC, White WB.
    Expert Rev Cardiovasc Ther; 2014 Jul; 12(7):791-8. PubMed ID: 24881461
    [Abstract] [Full Text] [Related]

  • 9. Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
    Barrios V, Escobar C.
    Expert Opin Pharmacother; 2013 Nov; 14(16):2249-61. PubMed ID: 24070321
    [Abstract] [Full Text] [Related]

  • 10. A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone.
    Weber MA, Sever P, Juhasz A, Roberts A, Cao C.
    J Renin Angiotensin Aldosterone Syst; 2018 Nov; 19(3):1470320318795000. PubMed ID: 30175930
    [Abstract] [Full Text] [Related]

  • 11. Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension.
    Ferdinand KC, Bakris GL, Cushman WC, Weber MA, Lloyd E, Wu J, White WB.
    Am J Cardiol; 2018 Nov 01; 122(9):1496-1505. PubMed ID: 30217371
    [Abstract] [Full Text] [Related]

  • 12. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
    Kusumoto K, Igata H, Ojima M, Tsuboi A, Imanishi M, Yamaguchi F, Sakamoto H, Kuroita T, Kawaguchi N, Nishigaki N, Nagaya H.
    Eur J Pharmacol; 2011 Nov 01; 669(1-3):84-93. PubMed ID: 21816148
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
    Barrios V, Boccanelli A, Ewald S, Girerd X, Heagerty A, Krzesinski JM, Lins R, Rodicio J, Stefenelli T, Woittiez A, Böhm M.
    Clin Drug Investig; 2007 Nov 01; 27(8):545-58. PubMed ID: 17638395
    [Abstract] [Full Text] [Related]

  • 14. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.
    Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A, Cao C, Kupfer S.
    J Clin Hypertens (Greenwich); 2011 Feb 01; 13(2):81-8. PubMed ID: 21272195
    [Abstract] [Full Text] [Related]

  • 15. Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension.
    Greathouse M.
    Vasc Health Risk Manag; 2006 Feb 01; 2(4):401-9. PubMed ID: 17323594
    [Abstract] [Full Text] [Related]

  • 16. Safety, tolerability, and efficacy of azilsartan medoxomil with or without chlorthalidone during and after 8 months of treatment for hypertension.
    Kipnes MS, Handley A, Lloyd E, Barger B, Roberts A.
    J Clin Hypertens (Greenwich); 2015 Mar 01; 17(3):183-92. PubMed ID: 25619410
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide.
    Chrysant SG, Weber MA, Wang AC, Hinman DJ.
    Am J Hypertens; 2004 Mar 01; 17(3):252-9. PubMed ID: 15001200
    [Abstract] [Full Text] [Related]

  • 18. Azilsartan medoxomil: a review of its use in hypertension.
    Perry CM.
    Clin Drug Investig; 2012 Sep 01; 32(9):621-39. PubMed ID: 22877322
    [Abstract] [Full Text] [Related]

  • 19. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study.
    Chrysant SG, Chavanu KJ, Xu J.
    Am J Cardiovasc Drugs; 2009 Sep 01; 9(4):241-51. PubMed ID: 19655819
    [Abstract] [Full Text] [Related]

  • 20. Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension.
    Shuster JE, Bleske BE, Dorsch MP.
    Vasc Health Risk Manag; 2012 Sep 01; 8():381-7. PubMed ID: 22745562
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.